tiprankstipranks
Trending News
More News >
NeurAxis, Inc. (NRXS)
:NRXS
US Market
Advertisement

NeurAxis, Inc. (NRXS) Earnings Dates, Call Summary & Reports

Compare
38 Followers

Earnings Data

Report Date
Apr 14, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
Last Year’s EPS
-0.23
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 11, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and successful milestones, including FDA indication expansions and strategic payer engagement. However, challenges remain with reimbursement, operating expenses, and uncertainty around the RED device. The sentiment is bolstered by strategic planning for 2026 with the new CPT code, but tempered by ongoing financial and market access challenges.
Company Guidance
During the NeurAxis, Inc. Third Quarter 2025 Financial Results Conference Call, CEO Brian Carrico and CFO Timothy Robert Henrichs provided extensive guidance on the company’s strategic focus and financial outlook. The company reported a 22% revenue increase to $811,000, marking the fifth consecutive quarter of double-digit growth. They highlighted the impending implementation of a new category one CPT code on January 1, 2026, as a catalyst for significant market expansion and revenue growth. Currently, NeurAxis has approximately 55 million covered lives and is actively engaging with payers to secure broader insurance coverage, particularly for pediatric patients. The company is also preparing for potential growth in adult markets with IV Stem, despite potential reimbursement challenges. Operating expenses increased by 25% to $2.8 million, attributed to heightened sales and marketing efforts and research and development investments. Despite a 27% increase in operating loss to $2.1 million, the company remains optimistic about the upcoming CPT code's impact on revenue, aiming for cash flow breakeven as adoption accelerates in 2026.
Revenue Growth
Q3 2025 revenue increased by 22% year over year, marking the fifth consecutive quarter of double-digit growth.
Successful Milestones Achieved
Achieved FDA indication expansion to functional abdominal pain and functional dyspepsia with associated nausea symptoms for both children and adults.
Strong Payer Engagement
Engagement with major payers is deemed comprehensive, with a focus on policy coverage expansion for pediatric use.
Positive Gross Margin
Gross margin for 2025 was 83.3%, showing resilience despite some declines from previous years.
Strategic Commercial Plan for 2026
Plans for broad adoption of IV Stem with new Category One CPT code effective January 1, 2026, promising improved reimbursement and adoption.
Cash Position Improved
Cash on hand was $4,400,000 as of September 2025, improved by an additional $2,800,000 raised in October 2025.

NeurAxis, Inc. (NRXS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

NRXS Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 14, 2026
2025 (Q4)
- / -
-0.23
Nov 11, 2025
2025 (Q3)
-0.20 / -0.24
-0.2514.38% (+0.01)
Aug 12, 2025
2025 (Q2)
-0.19 / -0.22
-0.42247.87% (+0.20)
May 12, 2025
2025 (Q1)
-0.24 / -0.33
-0.32-3.13% (-0.01)
Mar 20, 2025
2024 (Q4)
- / -0.20
-0.81674.88% (+0.61)
Nov 12, 2024
2024 (Q3)
- / -0.25
-1.3581.41% (+1.10)
Aug 09, 2024
2024 (Q2)
- / -0.42
-1.2165.12% (+0.79)
May 22, 2024
2024 (Q1)
- / -
-0.38
Apr 09, 2024
2023 (Q4)
-0.15 / -0.32
-0.3815.79% (+0.06)
Nov 20, 2023
2023 (Q3)
-0.17 / -1.35
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

NRXS Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 11, 2025
$2.56$2.41-5.86%
Aug 12, 2025
$2.43$2.49+2.47%
May 12, 2025
$2.00$2.32+16.00%
Mar 20, 2025
$2.29$2.27-0.87%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does NeurAxis, Inc. (NRXS) report earnings?
NeurAxis, Inc. (NRXS) is schdueled to report earning on Apr 14, 2026, Before Open (Confirmed).
    What is NeurAxis, Inc. (NRXS) earnings time?
    NeurAxis, Inc. (NRXS) earnings time is at Apr 14, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is NRXS EPS forecast?
          Currently, no data Available
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis